Accelerating Parkinson's Disease Clinical Research Through CHDR's Monocentre Recruitment Capabilities

Early-phase Parkinson’s disease (PD) trials often struggle with slow enrolment, inconsistent data, and operational complexity. A monocentre model addresses these challenges by centralizing data-intensive studies at a single site while leveraging a nationwide network of hospitals and neurologists.

This approach minimizes variability, accelerates recruitment, and ensures high-quality biomarker assessments. In practice, recruitment rates of up to four patients per week have been achieved, supported by umbrella protocols that streamline regulatory processes and enable seamless progression from double-blind phases to open-label extensions. Access to a proprietary database of over 5,000 genetically characterized PD patients, including one of the world’s highest frequencies of GBA1 variants, allows targeted enrolment for precision trials.

Sponsors benefit from integrated operational control, consistent pharmacodynamic evaluations, and reduced timelines, creating a scalable platform for innovation. For drug developers seeking rapid proof-of-concept and dose optimization, this model offers a proven pathway to de-risk early development and accelerate the transition to late-phase efficacy studies.